Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. | |
MedLine Citation:
|
PMID: 2095753 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Whether patients in clinical remission for acute lymphoblastic leukemia (ALL) continue to harbor leukemic cells is not known, because methods of detecting residual malignant cells have not been sufficiently sensitive. This information might be useful for predicting recurrence and determining the duration of therapy. METHODS: Using a sensitive new method--identifying complementarity-determining region III sequences with the polymerase chain reaction--we estimated the number of residual leukemic cells in the bone marrow of eight children with B-lineage lymphoblastic leukemia before and after remission. RESULTS: Induction chemotherapy produced a 3-to-4-log reduction in the number of leukemic cells. In all samples obtained up to 18 months after diagnosis, however, 0.004 to 2.6 percent of bone marrow nucleated cells were residual leukemic cells. Among the four patients studied more than 18 months after diagnosis, three had no detectable leukemic cells in marrow samples. Despite this, one of them, who was no longer receiving therapy, had a central nervous system relapse. In one patient receiving maintenance chemotherapy, there was a 60-fold increase in leukemic cells three months before bone marrow relapse. CONCLUSIONS: The complete disappearance of leukemic cells (or their reduction below our method's threshold of detection, 1 in 100,000 cells) may be necessary to achieve a cure of ALL. The quantification of residual leukemic cells in serial marrow aspirates during therapy may allow the early detection of relapse. |
Authors:
|
M Yamada; R Wasserman; B Lange; B A Reichard; R B Womer; G Rovera |
Related Documents
:
|
2006173 - Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory... 9108413 - Expression of the ret receptor tyrosine kinase and gdnfr-alpha in normal and leukemic h... 4059803 - Mast cells on the surface of the mucous membrane--a general feature of inflammatory rea... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The New England journal of medicine Volume: 323 ISSN: 0028-4793 ISO Abbreviation: N. Engl. J. Med. Publication Date: 1990 Aug |
Date Detail:
|
Created Date: 1990-08-30 Completed Date: 1990-08-30 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 448-55 Citation Subset: AIM; IM |
Affiliation:
|
Wistar Institute, Philadelphia, PA 19104. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Base Sequence Bone Marrow / pathology* Burkitt Lymphoma / drug therapy, pathology* Child Child, Preschool DNA, Neoplasm / analysis Female Humans Infant Male Molecular Sequence Data Polymerase Chain Reaction Time Factors |
Grant Support | |
ID/Acronym/Agency:
|
CA 10819/CA/NCI NIH HHS; CA 47983/CA/NCI NIH HHS |
Chemical | |
Reg. No./Substance:
|
0/DNA, Neoplasm |
Comments/Corrections | |
Comment In:
|
N Engl J Med. 1991 Mar 14;324(11):772-5
[PMID:
1997845
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Severe hemolysis after incomplete mitral valve repair.
Next Document: Earlobe crease and atherosclerosis. An autopsy study.